Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Empagliflozin on Podocyte Specific Proteins (Injury Markers) in African American Veterans With Non-Diabetic Chronic Kidney Disease

NCT06110130 is registered in ClinicalTrials.gov with Washington D.C. Veterans Affairs Medical Center as lead sponsor.

NCT NCT06110130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06110130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Empagliflozin on Podocyte Specific Proteins (Injury Markers) in African American Veterans With Non-Diabetic Chronic Kidney Disease
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Phase
Phase 4
Overall status
Recruiting
Start date
February 2, 2024
Completion date
December 1, 2028
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney diseases